Cas:205391-01-1 4,5-Diaminofluorescein-Isopropanol adduct (1:2) manufacturer & supplier

Chemical Name:4,5-Diaminofluorescein-Isopropanol adduct (1:2)

CAS.NO:205391-01-1

Synonyms:5,6-diamino-3′,6′-dihydroxyspiro[2-benzofuran-3,9′-xanthene]-1-one;Spiro[isobenzofuran-1(3H),9′-[9H]xanthen]-3-one, 5,6-diamino-3′,6′-dihydroxy-;5,6-Diamino-3′,6′-dihydroxy-3H-spiro[2-benzofuran-1,9′-xanthen]-3-one;4,5-Diaminofluorescein DAF-2

Molecular Formula:C₂₀H₁₄N₂O₅

Molecular Weight:362.336

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:760.8±60.0 °C at 760 mmHg

Density:1.7±0.1 g/cm3

Index of Refraction:1.848

PSA:128.03000

Exact Mass:362.090271

LogP:1.41

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5,6-diamino-3′,6′-dihydroxyspiro[2-benzofuran-3,9′-xanthene]-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,5-Diaminofluorescein DAF-2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,5-Diaminofluorescein DAF-2 Use and application,Spiro[isobenzofuran-1(3H),9′-[9H]xanthen]-3-one, 5,6-diamino-3′,6′-dihydroxy- technical grade,usp/ep/jp grade.

Related News: Soliris would need a “substantial discount” to reach a more appropriate price, according to its report. Using the widely leveraged measure for disease burden known as quality-adjusted life year (QALY), ICER calculated a range of $6,900 to achieve $50,000 per QALY to $25,700 to hit $200,000 per QALY. Thiourea, N-(4-nitrophenyl)-N’-(phenylmethyl)- manufacturers As for argenx’s efgartigimod, that drug hasn’t scored an FDA nod yet and its eventual cost-effectiveness will depend on its price. L-prolylglycyl-L-tyrosyl-L-lysyl-L-histidyl-L-threonine suppliers The group, after examining Soliris’ late-stage trial data, determined they’re highly certain it produces a small benefit to patients who are positive for anti-AChR antibodies, while there’s a “moderate certainty of a small or substantial net health benefit.” L-Serine, N-[N-(N-L-seryl-L-seryl)-L-threonyl]- vendor & factory This will entail workforce hiring of over 110 personnel too.,The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered.